Anzeige
❌
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
04.09.25 | 20:07
24,700 Euro
-3,21 % -0,820
Branche
Biotechnologie
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
24,70025,06004.09.
24,74024,98004.09.

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.08.Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi214PR NewswireSTOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049...
► Artikel lesen
21.08.Swedish Orphan Biovitrum AB: Sobi has completed issues of class C shares183PR NewswireSTOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025 resolved on directed issues of redeemable and convertible class...
► Artikel lesen
25.07.Ionis Pharma, Sobi Get Positive CHMP Opinion For TRYNGOLZA In Familial Chylomicronemia Syndrome17RTTNews
25.07.Sobi North America Announces Approval Of Doptelet For Pediatric ITP431AFX NewsSTOCKHOLM (dpa-AFX) - Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced the FDA approved Doptelet or avatrombopag for the treatment of thrombocytopenia...
► Artikel lesen
25.07.Swedish Orphan Biovitrum AB: TRYNGOLZA (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)409PR NewswireRecommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZAEuropean Commission...
► Artikel lesen
25.07.Sobi, Inc.: Sobi Announces U.S. Food and Drug Administration Approves Doptelet (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia ...179GlobeNewswire (Europe)Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in...
► Artikel lesen
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
16.07.Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlook6Seeking Alpha
16.07.Swedish Orphan Biovitrum AB: Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum353PR NewswireSTOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased...
► Artikel lesen
15.07.Swedish Orphan Biovitrum AB: The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes452PR NewswireSTOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved - for the purpose of ensuring that the company can...
► Artikel lesen
02.07.Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli7Zacks
02.07.Swedish Orphan Biovitrum AB: Invitation: Sobi's Q2 report269PR NewswireSobi plans to publish its report for the second quarter of 2025 on 16 July 2025 at 08:00 CEST. STOCKHOLM, July 2, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited...
► Artikel lesen
02.07.Regulatory tracker: Sobi's Gamifant gains new FDA approval in Still's disease2FiercePharma
01.07.Sobi agrees to pay up to $300M to reduce royalty payments to Apellis on Empaveli4FiercePharma
01.07.Apellis stock rises after $300 million royalty deal with Sobi2Investing.com
01.07.Apellis signs royalty purchase deal with Sobi for Aspaveli4Seeking Alpha
01.07.Swedish Orphan Biovitrum AB: Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli (systemic pegcetacoplan)494PR NewswireSTOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty...
► Artikel lesen
01.07.Apellis Pharmaceuticals, Inc.: Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli (systemic pegcetacoplan)5GlobeNewswire (USA)
30.06.FDA approves Sobi's Gamifant to treat severe inflammatory arthritis complication3PMLiVE
30.06.Sobi gains FDA approval for Gamifant to treat HLH/MAS1Pharmaceutical Technology
28.06.Swedish Orphan Biovitrum AB: FDA approves Gamifant (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease721PR NewswireApproval based on the pooled analysis of our pivotal EMERALD and NI-0501-06 studies, showing 54% of patients treated with Gamifant achieved complete response at week 8.STOCKHOLM, June 28...
► Artikel lesen
1 2 3 4 Weiter >>
67 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1